Compare BLMN & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLMN | IRWD |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 714.0M | 658.5M |
| IPO Year | 2012 | 2009 |
| Metric | BLMN | IRWD |
|---|---|---|
| Price | $8.85 | $3.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $7.88 | $7.67 |
| AVG Volume (30 Days) | 1.7M | ★ 2.1M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.99% | N/A |
| EPS Growth | 106.71 | ★ 1400.00 |
| EPS | ★ 0.65 | 0.24 |
| Revenue | ★ $4,213,346,000.00 | $298,276,000.00 |
| Revenue This Year | $2.07 | $57.95 |
| Revenue Next Year | $1.81 | $4.39 |
| P/E Ratio | ★ $13.55 | $14.83 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $5.19 | $0.72 |
| 52 Week High | $9.28 | $5.78 |
| Indicator | BLMN | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 58.99 | 38.43 |
| Support Level | $7.16 | $3.08 |
| Resistance Level | $9.28 | $3.95 |
| Average True Range (ATR) | 0.39 | 0.20 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 85.71 | 0.91 |
Bloomin Brands Inc is a casual dining restaurant company, with a portfolio of, differentiated restaurant concepts. Its restaurant portfolio includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill and Fleming's Prime Steakhouse & Wine Bar. Its restaurant concepts range in price point and degree of formality from casual (Outback Steakhouse and Carrabba's Italian Grill) to polished casual (Bonefish Grill) and fine dining (Fleming's Prime Steakhouse & Wine Bar). The U.S. segment includes all restaurants operating in the U.S. while franchised restaurants operating outside the U.S. are included in the international franchise segment.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.